Marty Makary, who was a top official leading drug policy, conducted polls on behalf of President Trump.

3 reports, 3 independent Updated May 26

Gone quiet Reached 3 outlets in its first 24 hours

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Marty Makary, who was a top official leading drug policy, conducted polls on behalf of President Trump.

Who's involved

What this event is mainly about

FDA Marty Makary Donald Trump

Keep exploring

Part of

An executive order was issued to accelerate research related to drug policy in the US. All 3 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Marty Makary
American surgeon and FDA Commissioner

Nothing else this week.
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02

Related events

Trump is expected to nominate Heidi Overton to lead the Food and Drug Administration.Aug 19

Coverage

Newest first; wire copies grouped

May 26dailycaller.com
May 26ktbb.com
Jul 26BloombergLawmakers Press FDA to Target Knockoff Weight-Loss Drugs (Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mou